Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948442 | 1.00 | CES2 (0.42) | CES2CES1SNCANFE2L2PARP1 | |
| SCHEMBL2947404 | 0.84 | CES2 (0.47) | CES2CES1PARP1MAOBKMT2A | |
| SCHEMBL2946647 | 0.80 | CES2 (0.39) | CES2CES1SNCAPARP1KMT2A | |
| SCHEMBL2947028 | 0.79 | UNG (0.43) | CES2CES1SNCAPARP1MAOB | |
| SCHEMBL2942718 | 0.79 | CES2 (0.35) | CES2CES1SNCASMN1; SMN2MAPT | |
| SCHEMBL2942720 | 0.79 | CES2 (0.35) | CES2CES1SNCASMN1; SMN2MAPT | |
| SCHEMBL2944822 | 0.75 | CES2 (0.47) | CES2CES1PARP1MAOBKMT2A | |
| SCHEMBL2942822 | 0.74 | ALOX5 (0.48) | MAOBKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL2942820 | 0.74 | ALOX5 (0.48) | MAOBKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL4352918 | 0.73 | CES2 (0.45) | CES2CES1PARP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076367-B2 | Benzimidazolylidene propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709519-B2 | Benzimidazolylidene propane-1,3 dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1752452-A9 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1752452-A1 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GPER1, GNRHR, AR | CES2 4083/4885CES1 1983/4885SNCA 3064/4885 |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | GPER1, GNRHR, AR | CES2 4228/4885CES1 2243/4885SNCA 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.